List of Viramune Xr drug patents
Viramune Xr is owned by Boehringer Ingelheim.
Viramune Xr contains Nevirapine.
Viramune Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Viramune Xr was authorised for market use on 25 March, 2011.
Viramune Xr is available in tablet, extended release;oral dosage forms.
Viramune Xr can be used as treatment of hiv-1 by once daily administration.
The generics of Viramune Xr are possible to be released after 12 March, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460704 | BOEHRINGER INGELHEIM | Extended release formulation of nevirapine |
Mar, 2029
(5 years from now) | |
Drugs and Companies using NEVIRAPINE ingredient
Market Authorisation Date: 25 March, 2011
Treatment: Treatment of hiv-1 by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIRAMUNE XR family patents
3
United States
2
Peru
1
Uruguay
1
Spain
1
Brazil
1
Colombia
1
New Zealand
1
Mexico
1
Argentina
1
Morocco
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Tunisia
1
South Africa
1
Canada
1
Japan
1
Hungary
1
Ukraine
1
Poland
1
Chile
1
Australia
1
Ecuador
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic